Additionally, their enhanced ability to readily cross the blood–brain barrier, compared with popular PPAR agonists, makes RXR agonists attractive candidates for the treatment of neurologic diseases (Cramer et al., 2012). This evidence concerns the gene PPARA and nervous system disorder.